GlassScriptPhysician profile
Howard J Tucker
NPI 1295784908
$951.57
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $105 · 2021: $261.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $309.86 | 2019 | |
| Lilly USA, LLC | $198.39 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $81.79 | 2019 | |
| Nestle Healthcare Nutrition INC. | $52.15 | 2021 | |
| Eisai INC. | $42.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.84 | 2019-2020 | |
| Csl Behring | $28.40 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $25.00 | 2019 | |
| Ucb, INC. | $21.87 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.73 | 2020 | |
| Abbvie INC. | $18.48 | 2021 | |
| Sk Life Science, INC. | $18.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.90 | 2021 | |
| Genentech USA, INC. | $16.33 | 2019 | |
| Acell, INC. | $15.77 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $15.46 | 2020 | |
| Tanabe Pharma America, INC. | $13.89 | 2019 | |
| Biogen, INC. | $12.26 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.